A naturally occurring E-series prostaglandin produced by the COX metabolism of ω-3 arachidonic acid. It was first isolated and characterized as a product of ram seminal vesicle microsomes. The relative abundance of Δ17-PGE1 in humans and other animals is low in comparison with PGE2, and is likely to be a reflection of precursor fatty acid abundance in the phospholipid PUFA reservoir. Definitive studies on the biosynthesis of Δ17-PGE1 in intact animals have not been done. Δ17-PGE1 is about half as potent as PGE1 as an inhibitor of ADP-induced aggregation of rabbit PRP. In human PRP, Δ17-PGE1 is a more potent antiplatelet agonist than PGE1, with an IC50 of about 30 nM.3 The vascular effects of Δ17-PGE1 have not been reported.
1. Samel, N., et al. 1987. Prostaglandins. 33: 137-146. PMID: 3473571
2. Kobzar, G., et al. 1993. Comp Biochem Physiol C. 106: 489-494. PMID: 7904921
3. Kobzar, G., et al. 1991. Comp Biochem Physiol C. 40: 179-180. PMID: 7904921
A Santa Cruz Biotecnologia, Inc. é a líder mundial no desenvolvimento de produtos para o mercado de pesquisa biomédica. Ligue para nós ligação gratuita 1-800-457-3801..
Direito de Reprodução© 2007-2021 Santa Cruz Biotechnology, Inc. Todos os direitos reservados. "Santa Cruz Biotechnology", Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", "EZ Touch" são marcas registradas da Santa Cruz Biotechnology, Inc. Todas as marcas registradas são propriedade dos seus respectivos donos.